Summit Therapeutics (SMMT) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.28), in-line with the analyst estimate of (GBP0.28).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ackman adds Netflix, Visa and Mastercard in portfolio revamp
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
- Live Ventures (LIVE) Reports Q3 Loss of $0.34
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
